<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604016</url>
  </required_header>
  <id_info>
    <org_study_id>ID-BVCL-401</org_study_id>
    <nct_id>NCT03604016</nct_id>
  </id_info>
  <brief_title>Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver</brief_title>
  <official_title>Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study to assess the antiviral activity and safety of Besifovir dipivoxil 150mg and
      L-carnitine 660mg compared to Tenofovir Alafenamide 25mg in chronic hepatitis B patients with
      Nonalcoholic fatty liver
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 23, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of subjects who showed HBV DNA undetected (less than 116 copies/mL (20 IU/mL)) at the 48 week</measure>
    <time_frame>at the 48th week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBV DNA undetected (less than 116 copies/mL (20 IU/mL)) at the 24 week</measure>
    <time_frame>at the 24th week</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The change of liver fat at 48 weeks</measure>
    <time_frame>at the 48th weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Besifovir dipivoxil+L-carnitine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Besifovir dipivoxil 150 mg and L-carnitine 330 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir Alafenamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir Alafenamide 25mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Besifovir dipivoxil</intervention_name>
    <description>Besifovir dipivoxil 150 mg</description>
    <arm_group_label>Besifovir dipivoxil+L-carnitine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-carnitine</intervention_name>
    <description>Besifovir dipivoxil 150 mg</description>
    <arm_group_label>Besifovir dipivoxil+L-carnitine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Alafenamide</intervention_name>
    <description>Tenofovir Alafenamide 25mg</description>
    <arm_group_label>Tenofovir Alafenamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 years of age and older, Male or female patients

          -  Chronic hepatitis B patients with Nonalcoholic fatty liver

          -  Patients who use oral anti-diabetic drug or drugs for hyperlipemia without any change
             in drug dosage within 2 month before screening visit

          -  Patients who have been explained about the trial and agreed to the consent

          -  Patients who agree with the approved method of contraception during the clinical trial

        Exclusion Criteria:

          -  Patients with hepatitis C virus, hepatitis D virus or human immunodeficiency virus

          -  Patients who has a history of liver transplantation or Child-Pugh score &gt;=8

          -  Alpha-fetoprotein (AFP) &gt; 50 ng/mL or Hepatocellular Carcinoma (HCC) patients

          -  Patients who have taken Besifovir or Vemlidy

          -  Among the patients treated with immunosuppressive drug within 6 months before
             screening, suspected case of the declined immunity in the opinion of the investigator

          -  Chronic alcoholism (Significant alcohol consumption: male &gt; 210 g/week, female&gt; 140
             g/week)

          -  Patients who take drugs that can cause hepatic steatosis

          -  Patient diagnosed with a malignant tumor within 5 years before screening or relapsed
             patient

          -  Patients with uncontrolled diabetes mellitus (HbA1c &gt; 9%) or using insulin

          -  Patients who participate in other clinical trials or is supposed to do so during the
             study period

          -  Pregnant or breast-feeding women or women who have plan to be pregnant.

          -  Patients with a history of hypersensitivity to the test drug or the components of the
             test drug

          -  Patients with moderate or severe renal impairment

          -  Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency
             or glucose-galactose malabsorption.

          -  History within the past one years or presence of drug abuse or alcoholism.

          -  Patient has serious disease judged by investigator such as heart failure, renal
             failure, and pancreatitis

          -  Patient has liver diseases except chronic hepatitis B (i.e. hematochromatosis,
             alcoholic liver disease, nonalcoholic fatty liver disease, alpha-1 antitrypsin
             deficiency etc.)

          -  Patient has history of organ transplantation

          -  Patient concerned about the decline in daily activity or not able to understand the
             objectives and methods due to the psychiatric problems

          -  Patients who are considered to be unacceptable in this study under the opinion of the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Minju Hong</last_name>
    <phone>82105263644</phone>
    <email>mjhong@ildong.com</email>
  </overall_contact>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

